Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (February 2019)
19 slides from Can-fite Biopharma's investor presentation, Feb 1, 2019
Slide 1: Can-Fite Presentation
(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation Pnina Fishman, CEO Motti Farbstein, CFO February 2019 (NYSE American: CANF) (TASE:CFBI)
Slide 2: Forward Looking Statement
(NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 • This presentation contains forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strate
Slide 3: Company Profile
(NYSE American: CANF) (TASE:CFBI) 3 Company Profile • Highly experienced management, clinical and regulatory team • Leading KOLs serve on CAB • Successful corporate partnerships and licensing deals • Advanced clinical stage drug development company with a compelling platform technology • Small molec
Slide 4: Short Term Milestones
(NYSE American: CANF) (TASE:CFBI) 4 Short Term Milestones 4 Data Release from Namodenoson Phase II Clinical Studies * : 1. Q1/2019 Phase II Advanced Liver Cancer (Fast track and Orphan Status) 2. Q3/2019 Phase II NASH Study *Estimated timelines
Slide 5: From Concept to Technology
(NYSE American: CANF) (TASE:CFBI) From Concept to Technology 5 Company platform technology mimics natural body mechanism to combat cancer and inflammation
Slide 6: Drug Development Pipeline
(NYSE American: CANF) (TASE:CFBI) Drug Development Pipeline 6 ~$ 35 B ~$11.4B ~$ 1.4 B ~$ 35 B ~$3.2B Market *Sources: Visiongain estimates global psoriasis drug market will be $ 11.4 bB by 2020 and the global rheumatoid arthritis drug market will be $ 34.6 B by 2020 ; Datamonitor estimates the HCC
Slide 7: Corporate Partnerships - Out-licensing deals
(NYSE American: CANF) (TASE:CFBI) [Trades on Hong Kong Stock Exchange (Ticker : 867 )] • Exclusive regional license to develop, register & market Piclidenoson & Namodenoson in China, Hong Kong, Macao and Taiwan. [ Trades on TSX : (Ticker : CPH)] • Exclusive regional license to distribute Piclidenoso
Slide 8: Piclidenoson Rheumatoid Arthritis & Psoriasis Mechanism of Action
(NYSE American: CANF) (TASE:CFBI) 8 Piclidenoson Rheumatoid Arthritis & Psoriasis Piclidenoson – Anti - Inflammatory Drug Mechanism of Action
Slide 9: Rheumatoid Arthritis - Phase IIb Data
(NYSE American: CANF) (TASE:CFBI) Phase IIb study, Placebo controlled; 79 patients – Positively concluded Rheumatoid Arthritis - Phase IIb Data 9 *MTX, Biological Drugs *MTX, Biological Drugs 1 mg *
Slide 10: Rheumatoid Arthritis - Phase III Study Ongoing
(NYSE American: CANF) (TASE:CFBI) Rheumatoid Arthritis - Phase III Study Ongoing ACRobat – Can - Fite’s Phase III clinical study is designed to establish Piclidenoson as non - inferior to MTX in newly diagnosed patients with moderate - to - severe RA This Protocol is in Agreement with EMA • Randomiz
Slide 11: Psoriasis Phase II/III Data vs. Celgene's Otezla
(NYSE American: CANF) (TASE:CFBI) Psoriasis Phase II/III Data vs. Celgene ’ s Otezla * 11 • Phase II/III study did not achieve the primary endpoint of PASI 75 at 12 weeks • Otezla ® sales were $ 1.3 billion in 2017, 26% increase over 2016 1 • Peak Otezla® sales estimated at $2.35 billion in 2020 2 S
Slide 12: Psoriasis Phase III Study - Ongoing
(NYSE American: CANF) (TASE:CFBI) Psoriasis Phase III Study - Ongoing Comfort – Phase III clinical study is designed to establish Piclidenoson superiority vs. placebo and non - inferiorty vs. Otezla in patients with moderate - to - severe Plaque Psoriasis This Protocol is in Agreement with EMA • Ran
Slide 13: Namodenoson Advanced Liver Cancer & NASH Mechanism of Action
(NYSE American: CANF) (TASE:CFBI) 13 Namodenoson Advanced Liver Cancer & NASH Namodenoson – Liver Disease Drug Mechanism of Action
Slide 14: Namodenoson for the Treatment of Liver Cancer
(NYSE American: CANF) (TASE:CFBI) Namodenoson for the Treatment of Liver Cancer • Excellent safety profile and lack of hepatotoxicity • Prolongation of survival time • Regression of skin tumor metastases • Stable disease (22 %) Regulatory Status 14 Phase I/II Positive Results Orphan Drug Designation
Slide 15: Liver Cancer - Phase II Study Completed Enrollment
(NYSE American: CANF) (TASE:CFBI) Phase II - Study Protocol • Second - Line Treatment • Advanced Hepatocellular Carcinoma; Child - Pugh B • 78 patients • US, Europe and Israel • Primary end point: overall survival • Patient enrollment completed August 2017 • Currently following survival data and wil
Slide 16: Namodenoson for the Treatment of NASH
(NYSE American: CANF) (TASE:CFBI) Namodenoson for the Treatment of NASH 16 Sources: 1 ) Study published in Hepatology, 2 ) NIH, 3 ) Study published in Gastroenterology, 4 ) Deutsche Bank “ America ’ s Greatest Health Risk ” – Scientific American, 2015 x 17 % - 33 % Prevalence of NAFLD in the U.S.
Slide 17: NASH - Excellent Pre-clinical Data
(NYSE American: CANF) (TASE:CFBI) NASH – Excellent Pre - clinical Data 17 Namodenoson markedly improved liver function & pathology in NASH experimental models (STAM & CCL4) x Anti - inflammatory - Namodenoson reduces NAFLD Activity Score (NAS) in STAM model x Anti - Fibrotic effect - in vitro and
Slide 18: NASH - Phase II Study
(NYSE American: CANF) (TASE:CFBI) NASH – Phase II Study 18 Leading KOLs ( Dr. Freidman ; Mount Sinai, Dr . Arun Sanyal ; Virginia University, Dr. Safadi ; Hadassah Jerusalem), on SAB and have advised on protocol design • Multicenter, randomized, double - blinded, placebo - controlled, dose - find
Slide 19: Spotlight on Milestones
(NYSE American: CANF) (TASE:CFBI) Spotlight on Milestones 19 *Sources: Visiongain estimates global psoriasis drug market will be $ 11.4 by 2020 and the global rheumatoid arthritis drug market will be $ 34.6 b by 2020 ; Datamonitor estimates the HCC drug market at $ 1.4 b in 2019 ; Grand View Researc
Can-Fite BioPharma — Investor Presentation (February 2019) on 6ix